NCT01495000已完成3 期
A Six-Month Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Denosumab in Indian Postmenopausal Women With Osteoporosis
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 250
- 试验地点
- 1
- 主要终点
- Mean Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 6
研究概览
简要总结
The purpose of this study is to determine if denosumab is effective in increasing bone mineral density at the lumbar spine in Indian postmenopausal women with osteoporosis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 55 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Ambulatory Indian postmenopausal women with osteoporosis
- •greater than 5 years postmenopausal
- •aged 55 to 75 years old
- •absolute bone mineral density value consistent with a T-score less than -2.5 and greater than - 4.0 at the either the lumbar spine or total hip, as measured by dual energy x-ray absorptiometry. Subjects with a T-score less than or equal to -4.0 are at very high risk for fracture and will be excluded.
排除标准
- •previous or current metabolic bone disease, Paget's or Cushing's disease, or hyperprolactinemia
- •current hypo- or hyperparathyroidism or hypo- or hyperthyroidism unless on stable thyroid replacement therapy and TSH level meets criteria
- •rheumatoid arthritis
- •cirrhosis of the liver or unstable liver disease or ALT or AST greater than or equal to 2.0 times the upper limit of normal, or alkaline phosphatase and bilirubin greater than or equal to 1.5 times the upper limit of normal
- •medications used to treat osteoporosis, defined for type and duration of use, and including IV and oral bisphosphonates
- •medications that affect bone metabolism including parathyroid hormone or derivatives; anabolic steroids or testosterone; glucocorticosteroids; systemic hormone replacement therapy; selective estrogen receptor modulators; tibolone, calcitonin, and calcitriol or vitamin D derivatives; other bone active drugs including anticonvulsives (but not benzodiazepines) and heparin; chronic systemic ketoconazole, androgens, ACTH, cinacalcet, aluminum, lithium, protease inhibitors, methotrexate, and gonadotropin-releasing hormone agonists
- •malignancy within 5 years except certain resected types
- •malabsorption syndrome or gastrointestinal disorders associated with malabsorption
- •abnormal calcium level
- •vitamin D deficiency
- •any laboratory abnormality that will prevent the subject from completing the study or interferes with interpretation of study results
- •oral or dental conditions including current or past history of osteomyelitis or osteonecrosis of the jaw; active dental or jaw condition with requires oral surgery; planned invasive dental procedure; un-healed dental or oral surgery
- •any disorder that compromises the ability of the subject to give written informed consent or to comply with study procedures
- •any physical or psychiatric disorder that will prevent the subject from completing the study or interferes with study results
- •known to have tested positive for HIV
- •less than two lumbar vertebrae evaluable for DXA measurements
- •height, weight, or girth that may preclude accurate DXA measurements
- •drug or alcohol abuse within 12 months that interferes with understanding or completing the study
- •known sensitivity to mammalian cell-derived drug products
- •use of an investigational drug or device within 30 days of enrollment or currently receiving other investigational agent(s)
研究组 & 干预措施
Arm 1
Experimental
denosumab 60mg subcutaneous injection, single dose at the start of the 6-month double-blind treatment
干预措施: denosumab (Drug)
Arm 2
Placebo Comparator
placebo subcutaneous injection, single dose at the start of the 6-month double-blind treatment
干预措施: placebo (Drug)
结局指标
主要结局
Mean Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 6
时间窗: Baseline and Month 6
Bone mineral density (BMD) at the lumbar spine was measured by the dual-energy x-ray absorptiometry (DXA) scanner. The mean percent change from Baseline in BMD was calculated as: (value at Month 6 minus Baseline value) \* 100 / Baseline value. Analysis was performed using an Analysis of Covariance (ANCOVA) model with terms for treatment and baseline BMD at the lumbar spine (as a continuous covariate).
次要结局
- Mean Percent Change From Baseline in BMD at the Total Hip, Femoral Neck, and Trochanter at Month 6(Baseline and Month 6)
- Number of Participants With the Indicated Laboratory Parameter Values of Potential Clinical Concern at Month 6(Month 6)
- Change From Baseline in Albumin/Globulin Ratio and Blood Urea Nitrogen (BUN)/Creatinine Ratio at Month 6(Baseline and Month 6)
- Change From Baseline in Alkaline Phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase, Creatinine Kinase, Gamma Glutamyl Transferase, and Lactate Dehydrogenase at Month 6(Baseline and Month 6)
- Median Percent Change From Baseline in Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (s-CTX) and Serum Procollagen Type IN Propeptide (s-PINP) Markers at Months 1, 3, and 6(Baseline; Months 1, 3, and 6)
- Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE)(From Baseline up to Month 6)
- Change From Baseline in Hematocrit at Month 6(Baseline and Month 6)
- Number of Participants With a Change From Baseline in Vital Signs of Potential Clinical Concern at Months 1, 3, and 6(Baseline; Months 1, 3, and 6)
- Change From Baseline in Calcium Corrected, Calcium, Chloride, Glucose, Potassium, Magnesium, Sodium, Phosphorus Inorganic, Triglycerides, Urea/BUN, and Very Low-density Lipoproteins (VLDL) Cholesterol Calculation at Month 6(Baseline and Month 6)
- Change From Baseline in Mean Corpuscle Hemoglobin at Month 6(Baseline and Month 6)
- Change From Baseline in Albumin, Hemoglobin, Mean Corpuscle Hemoglobin Concentration (Conc.), and Total Protein at Month 6(Baseline and Month 6)
- Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Segmented Neutrophils, Total Neutrophils, Platelet Count, and White Blood Cell Count Month 6(Baseline and Month 6)
- Change From Baseline in Direct Bilirubin, Indirect Bilirubin, Total Bilirubin, Creatinine, and Uric Acid at Month 6(Baseline and Month 6)
- Change From Baseline in Mean Corpuscular Volume at Month 6(Baseline and Month 6)
- Change From Baseline in Red Blood Cell Count at Month 6(Baseline and Month 6)
- Change From Baseline in Red Cell Distribution Width at Month 6(Baseline and Month 6)
- Number of Participants With Positive and Negative Results for Anti-body Formation to Denosumab at Month 6(Month 6)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Study in Korean Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of DenosumabOsteoporosis, PostmenopausalNCT01457950GlaxoSmithKline135
已完成
3 期
Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot StudyBone DensityBone LossEating DisorderAtypical Anorexia NervosaAnorexia NervosaNCT03292146Massachusetts General Hospital30
已完成
2 期
Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral DensityLow Bone Mineral DensityNCT00043186Amgen412
已完成
2 期
Efficacy, Safety and Tolerability of Romosozumab in the Treatment of Japanese Women With Postmenopausal OsteoporosisPostmenopausal Osteoporosis (PMO)NCT01992159Amgen252
已完成
3 期
Effects of Romosozumab on Bone Density in Women With Anorexia NervosaBone Density, LowBone LossEating DisordersAnorexia NervosaNCT04779216Karen Klahr Miller, MD30